FCN3 and hepatocellular carcinoma: The present research was the first to identify FCN3 as an endogenous blocker of the Wnt/β-catenin pathway in HCC that inhibited Treg activation and reduced immunosuppressive cytokines (TGF-β1 and IL-10), thereby expanding current knowledge.